The S.E.C. alleged shortcomings in analysis mentioned to assist the drug, and its developer agreed to a $40 million settlement. Some consultants surprise why scientific trials haven’t been stopped.
The S.E.C. alleged shortcomings in analysis mentioned to assist the drug, and its developer agreed to a $40 million settlement. Some consultants surprise why scientific trials haven’t been stopped.
Sign in to your account